Shares of Telomir Pharmaceuticals, Inc. rose significantly in after-hours trading on Wednesday, regaining lost ground following a promising update about its anti-aging drug, Telomir-1. After shedding 5.4% during regular market hours to close at $4.20, the stock climbed by 4.7% post-market to $4.40. This reversal came after the company announced pre-clinical trial results highlighting the […]
Coya Therapeutics Inc. (NASDAQ: COYA) witnessed a 9% increase in its share value after securing $10 million through a private placement. The biotechnology firm, specializing in developing therapies targeting regulatory T cells (Tregs), issued 1.4 million common shares at $7.25 each. The transaction drew significant interest from institutional and accredited investors, reflecting confidence in Coya’s […]
Actinogen Medical has raised 11.1 million AUD in a significant capital raise led by its CEO, Dr. Steven Gourlay, who personally invested 1 million AUD. The funds are aimed at accelerating the pivotal Phase 2b/3 trial for its promising Alzheimer’s treatment, Xanamem. This decisive move aims to fast-track patient enrolment and bring the potential breakthrough […]
The U.S. Food and Drug Administration’s review of Humacyte, Inc.’s innovative vascular trauma treatment, known as the acellular tissue engineered vessel (ATEV), has hit an unexpected delay, causing concern and curiosity in the medical and investment communities. Originally slated for completion by August 10, 2024, the FDA has not specified a new review completion date, […]
Recursion Pharmaceuticals Inc. (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have announced a landmark merger, combining their strengths to form a formidable entity in drug discovery and development. This strategic union is set to enhance their technological capabilities and expand their clinical pipeline, paving the way for more effective and affordable medicines. Key Details of […]
In a significant move within the biotechnology industry, AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical company, has completed the acquisition of Celsius Therapeutics, Inc., a pioneer in the development of therapies for inflammatory diseases. This acquisition, valued at $250 million in cash, underscores AbbVie’s strategic commitment to expanding its immunology portfolio by incorporating Celsius’ promising […]
MediLink Therapeutics (Suzhou) Co., Ltd., a prominent clinical-stage biotech company, has entered into a significant new strategic collaboration with BioNTech SE, a leader in next-generation immunotherapy. This collaboration involves an exclusive option for BioNTech to secure a global license to utilize MediLink’s innovative TMALIN antibody-drug conjugate (ADC) platform for several novel targets. A Lucrative Collaboration […]
Innovent Biologics, Inc. (HKEX: 01801) has announced remarkable results from the CLEAR-1 Phase 3 registrational study of its novel drug, picankibart (R & D code: IBI112), signaling a major breakthrough in psoriasis treatment. The study demonstrated that picankibart, a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection, met all primary and key secondary endpoints, showcasing its […]
In a significant move towards sustainability and innovation, Checkerspot, Inc., a pioneering biotechnology company recognized for its renewable oils derived from microalgae fermentation, and AAK AB, a global leader in plant-based fats and oils, have officially announced a joint development agreement. This groundbreaking partnership aims to develop, scale, and bring to the market an alternative […]
Merck has embarked on a monumental investment venture, injecting more than €300 million into the construction of a new Bioprocessing Production Center located in Daejeon, South Korea. This initiative stands as the most significant investment by Merck’s Life Science business sector in the Asia-Pacific region to date, underscoring the company’s dedication to expanding its operations […]